Astonea Labs Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 1,320,000 (47%) | — | ₹1,782 Cr |
| NII (HNI) | — | 399,000 (14%) | — | ₹539 Cr |
| Retail | — | 927,000 (33%) | — | ₹1,251 Cr |
| Market Maker | — | 144,000 (5%) | — | ₹19 Cr |
| Σ Total | — | 2,790,000 (100%) | — | ₹37,665 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,000 | ₹135,000 |
| Retail (Max) | 13 | 13,000 | ₹1,755,000 |
| S-HNI (Min) | 14 | 14,000 | ₹1,890,000 |
| B-HNI (Min) | 67 | 67,000 | ₹9,045,000 |
Financial Statements Amount in ₹ Crore
| Metric | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 70 | 80 | 67 |
| Profit After Tax | 4 | 4 | 1 |
| Net Worth | 17 | 12 | 8 |
| Total Assets | 97 | 81 | 64 |
| Reserves & Surplus | 10 | 4 | 4 |
| Total Borrowing | 49 | 42 | 36 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Funding of expenses proposed to be incurred towards registration in Bolivia, South America – 1.29
- Purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols, on the 2nd floor of the Existing Premises – 5.23
- Advertising, marketing and brand building – 4.95
- Investment in procuring hardware and software – 0.68
- Funding of working capital requirements of the company – 19.75
- General corporate purposes – 1.99
Company Overview
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies both within India and internationally.
The company manufactures and markets a variety of pharmaceutical and cosmetic products, including antibiotics, anti-cold medicines, antihistamines, and treatments for diabetes, heart, gynecological issues, infections, and more.
The company offers skin, tooth, and hair care products in forms like gels, creams, and serums, and also trades packaging and raw materials for pharmaceutical and cosmetic industries, meeting industry standards.
The company engages in contract manufacturing of pharmaceutical and cosmetic products, markets its own brands "Glow Up" and "Regero," plans to launch "Avicel," and exports to countries like Iraq and Yemen.
Produts and Offerings:
- Products under our own brands: The company markets “Glow Up” skincare and “Regero” pharma products, offering diverse affordable solutions.
- Products under contract manufacturing: The company provides pharmaceutical and cosmetic products under contract manufacturing, primarily for domestic and export markets.
As of August 16, 2024, the company had 217 employees on payroll.
Competitive Strengths:
- Experienced management and dedicated employee base
- Scalable business model
- Wide and diverse range of product offerings
- Quality Service